Jun 2026 (Q2 FY26) — Jul 30, 2026
Forrester Research Q2 FY26 — AI-Driven Engagement and Maintained Guidance
Read the full callForrester Research (FORR) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Forrester Research earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 100 | −10.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.4 | −2.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 15.3 | +289.8% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$11.94 +1.96% · +$0.23
Performance +34.8% 1Y
1Y: $8.86 on 14 Oct 2025 → $11.94. High $12.65 (4 Sept 2026), low $5.05 (10 Apr 2026).
- Previous close
- $11.71
- 52-week range
- $5.05 – $12.65
- One year
- +38.19%
Overview
- Symbol
- FORR
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Forrester Research earnings calls (FORR)
Financials
What the filings say
Net profit, year on year: +290% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 103 | 108 | 90 | 112 | 94 | 101 | 85 | 100 |
| Expenses | 103 | 109 | 177 | 105 | 90 | 138 | 104 | 97 |
| Operating profit | -1 | -1 | -88 | 7 | 4 | -37 | -19 | 3 |
| Operating margin | −0.7% | −0.5% | −97.5% | 6.2% | 4.7% | −36.6% | −21.8% | 3.4% |
| Profit before tax | -1 | 1 | -88 | 7 | -2 | -37 | -19 | 3 |
| Tax rate | −439.9% | 53.3% | 1.2% | 45.0% | −25.9% | 7.3% | −16.6% | −423.6% |
| Net profit | -6 | 0 | -87 | 4 | -2 | -34 | -22 | 15 |
| EPS ($ per share) | -0.30 | — | -4.62 | 0.21 | -0.11 | — | -1.14 | 0.79 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 128 | 118 | 128 | 153 | 175 | 178 | 172 | 53 |
| Total liabilities | 202 | 481 | 458 | 476 | 387 | 324 | 274 | 278 |
| Fixed assets | 22 | 30 | 27 | 28 | 23 | 19 | 12 | 11 |
| Total assets | 354 | 639 | 644 | 680 | 608 | 564 | 504 | 404 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 38 | 48 | 48 | 107 | 39 | 22 | -4 | 21 |
| Cash from investing | 40 | 250 | -5 | -29 | -7 | -37 | 5 | -14 |
| Cash from financing | -14 | 129 | -24 | -49 | -39 | -18 | -16 | -3 |
| Net cash flow | 61 | -71 | 21 | 27 | -12 | -31 | -17 | 7 |
| Capital expenditure | -5 | -12 | -9 | -11 | -6 | -5 | -3 | -3 |
| Free cash flow | 33 | 37 | 39 | 96 | 34 | 16 | -7 | 18 |
Insider filings
61 filings between Dec 1, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$198.9K
3 sales by 3 insiders
Compensation
not trading decisions- 5
- Award — granted as compensation
- 26
- Option exercise — converted options into shares
- 27
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Finn Leo Christian | — | $82.4K | Aug 20, 2026 |
| Darrah Ryan | — | $58.9K | Aug 20, 2026 |
| Johnson Carrie | — | $57.5K | Aug 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Favre Christophe Chief Sales Officer | Tax withheld | 257 | $3.1K |
| Sep 1, 2026 | Favre Christophe Chief Sales Officer | Option exercise | 552 | $0 |
| Aug 20, 2026 | Darrah Ryan Chief Legal Officer | Sale | 5,000 | $58.9K |
| Aug 20, 2026 | Finn Leo Christian Chief Financial Officer | Sale | 7,000 | $82.4K |
| Aug 13, 2026 | Johnson Carrie Chief Product Officer | Sale | 5,000 | $57.5K |
| Aug 1, 2026 | Facemire Michael Chief Technology Officer | Tax withheld | 1,102 | $12.7K |
| Aug 1, 2026 | Facemire Michael Chief Technology Officer | Option exercise | 2,605 | $0 |
| Aug 1, 2026 | Favre Christophe Chief Sales Officer | Option exercise | 634 | $0 |
| Aug 1, 2026 | Cox Andrew Chief Marketing Officer | Option exercise | 308 | $0 |
| Aug 1, 2026 | Favre Christophe Chief Sales Officer | Tax withheld | 301 | $3.5K |
| Aug 1, 2026 | Chouinard Scott Chief Accounting Officer | Tax withheld | 271 | $3.1K |
| Aug 1, 2026 | Chouinard Scott Chief Accounting Officer | Option exercise | 925 | $0 |
| Aug 1, 2026 | Cox Andrew Chief Marketing Officer | Tax withheld | 106 | $1.2K |
| Jun 1, 2026 | Cox Andrew Chief Marketing Officer | Tax withheld | 1,568 | $11.3K |
| Jun 1, 2026 | Gonsalves Jobina Chief People Officer | Option exercise | 4,913 | $0 |
| Jun 1, 2026 | Gonsalves Jobina Chief People Officer | Tax withheld | 1,441 | $10.4K |
| Jun 1, 2026 | Cox Andrew Chief Marketing Officer | Option exercise | 4,264 | $0 |
| Jun 1, 2026 | BRADFORD NEIL Director | Tax withheld | 198 | $1.4K |
| May 12, 2026 | Romine Warren N Director | Award | 8,000 | $0 |
| May 12, 2026 | Bennett Robert Paul Director | Award | 8,000 | $0 |
| May 12, 2026 | Friscia Anthony J Director | Award | 8,000 | $0 |
| May 12, 2026 | BRADFORD NEIL Director | Award | 8,000 | $0 |
| May 12, 2026 | Munchbach Cory Director | Award | 8,000 | $0 |
| Apr 1, 2026 | Favre Christophe Chief Sales Officer | Option exercise | 3,177 | $0 |
| Apr 1, 2026 | Favre Christophe Chief Sales Officer | Tax withheld | 1,532 | $8.3K |
| Apr 1, 2026 | Leaver Sharyn Chief Research Officer | Option exercise | 10,451 | $0 |
| Apr 1, 2026 | Darrah Ryan Chief Legal Officer | Tax withheld | 3,641 | $19.6K |
| Apr 1, 2026 | Darrah Ryan Chief Legal Officer | Option exercise | 9,318 | $0 |
| Apr 1, 2026 | Facemire Michael Chief Technology Officer | Tax withheld | 2,855 | $15.4K |
| Apr 1, 2026 | Leaver Sharyn Chief Research Officer | Tax withheld | 2,956 | $15.9K |
| Apr 1, 2026 | Cox Andrew Chief Marketing Officer | Option exercise | 1,816 | $0 |
| Apr 1, 2026 | Facemire Michael Chief Technology Officer | Option exercise | 5,994 | $0 |
| Apr 1, 2026 | Johnson Carrie Chief Product Officer | Option exercise | 14,335 | $0 |
| Apr 1, 2026 | Gonsalves Jobina Chief People Officer | Tax withheld | 1,732 | $9.3K |
| Apr 1, 2026 | Cox Andrew Chief Marketing Officer | Tax withheld | 723 | $3.9K |
| Apr 1, 2026 | Gonsalves Jobina Chief People Officer | Option exercise | 5,000 | $0 |
| Apr 1, 2026 | Chouinard Scott Chief Accounting Officer | Tax withheld | 1,608 | $8.7K |
| Apr 1, 2026 | Chouinard Scott Chief Accounting Officer | Option exercise | 4,645 | $0 |
| Apr 1, 2026 | Finn Leo Christian Chief Financial Officer | Tax withheld | 4,207 | $22.7K |
| Apr 1, 2026 | Finn Leo Christian Chief Financial Officer | Option exercise | 14,335 | $0 |
| Apr 1, 2026 | Johnson Carrie Chief Product Officer | Tax withheld | 5,353 | $28.9K |
| Mar 1, 2026 | Leaver Sharyn Chief Research Officer | Option exercise | 4,073 | $0 |
| Mar 1, 2026 | Darrah Ryan Chief Legal Officer | Tax withheld | 1,469 | $8.8K |
| Mar 1, 2026 | Darrah Ryan Chief Legal Officer | Option exercise | 3,446 | $0 |
| Mar 1, 2026 | Cox Andrew Chief Marketing Officer | Tax withheld | 75 | $449 |
| Mar 1, 2026 | Cox Andrew Chief Marketing Officer | Option exercise | 190 | $0 |
| Mar 1, 2026 | Favre Christophe Chief Sales Officer | Tax withheld | 196 | $1.2K |
| Mar 1, 2026 | Favre Christophe Chief Sales Officer | Option exercise | 408 | $0 |
| Mar 1, 2026 | Facemire Michael Chief Technology Officer | Tax withheld | 136 | $813 |
| Mar 1, 2026 | Facemire Michael Chief Technology Officer | Option exercise | 288 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for FORRESTER RESEARCH, INC.
Free account. Everything above stays public.
Write why you follow FORRESTER RESEARCH, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading